Efficacy of Abrocitinib in Patients Based on Prior Biologic Treatment History: A Post Hoc Analysis of JADE MONO-1, JADE MONO-2, and JADE REGIMEN
Guttman-Yasskey E, Gooderham M, Ardern-Jones M, Ameen M, Geng B, Biswas P, Bhambri A, Alderfer J, Watkins M.
AAD 2025
- 美国皮肤病学会年会 2025
| 皮肤病 | 特应性皮炎
Treatment with abrocitinib reduces circulating, skin homing and resident memory T cells in AD samples in vitro and ex vivo, and the severity of disease flares in a humanized mouse model
Koudounas S, Zondler L, Fehrholz M, Gilhar A, Ludwig R, Reich K, Watkins M, Pappelbaum K, Piccini I, Bertolini M.
AAD 2025
- 美国皮肤病学会年会 2025
| 皮肤病 | 特应性皮炎
Treatment patterns and effectiveness of Abrocitinib in atopic dermatitis- Interim analysis on real-world data in Abrocitinib Chinese rEgistry on AD (AHEAD)
Zhang L, Min W, Wu Z, Chen X, Zhu H, Li S, Han J, Miao G, Wu L, Zhu R, Gao X.
AAD 2025
- 美国皮肤病学会年会 2025
| 皮肤病 | 特应性皮炎
JAK3/TEC kinase pathways are active in alopecia areata (AA) lesions, and their inhibition with Ritlecitinib prevents αCD3/αCD28+IL-2 induced immune privilege collapse in healthy hair follicles ex vivo
Lejeune A, Viola-Söhnlein J, Rouillé T, Kieras E, Martin D, Telliez J, Berg L, Piccini I, Pappelbaum K, Edelkamp J, Bertolini M.
AAD 2025
- 美国皮肤病学会年会 2025
| 皮肤病 | 斑秃
